title: Distinguishing CML LSCs from HSCs using CD26.
abstract: In this issue of Blood, Herrmann et al elegantly demonstrate that CD26 is a new, specific chronic myeloid leukemia (CML) stem cell biomarker that phenotypically distinguishes leukemic stem cells (LSCs) from normal hematopoietic stem cells (HSCs), and that it is a potential therapeutic target in CML.
authors.affiliation: British Columbia Cancer Agency; University of British Columbia.
authors.forename: Xiaoyan
authors.initials: X
authors.lastname: Jiang
mesh_terms: D000818:Animals; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000378:metabolism*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000378:metabolism*; D008297:Male; D014411:Neoplastic Stem Cells / Q000378:metabolism*
chemical_list: D016044:Fusion Proteins, bcr-abl; D018819:Dipeptidyl Peptidase 4